Clinical Trials Logo

Clinical Trial Summary

The role of perioperative chemotherapy in potentially operable advanced gastric cancer (AGC) with regional lymph node metastasis is still in the area of controversy. The aim of this study is to evaluate the efficacy and toxicity of folinic acid (FA), infusional 5-fluorouracil (5-FU), and oxaliplatin (modified FOLFOX6) in potentially resectable AGC with regional lymph node (LN) metastasis.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01851941
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 2
Start date October 2004

See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Completed NCT00821990 - Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer Phase 3
Recruiting NCT04385641 - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer N/A
Completed NCT01248403 - A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy Phase 3
Not yet recruiting NCT01206218 - Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer Phase 2/Phase 3
Completed NCT00976768 - Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin Phase 2
Active, not recruiting NCT03223376 - A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) Phase 3
Completed NCT03609359 - Lenvatinib and Pembrolizumab Simultaneous Combination Study Phase 2
Completed NCT03350477 - Bioinformation Therapy for Gastric Cancer Phase 2/Phase 3
Completed NCT02935634 - A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Phase 2
Active, not recruiting NCT03579784 - Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer Phase 2
Completed NCT02952729 - Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Phase 1
Recruiting NCT02072317 - Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Phase 2
Completed NCT01503372 - FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer Phase 2
Completed NCT01472250 - A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China N/A
Terminated NCT01402401 - Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients Phase 2
Recruiting NCT01015339 - Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 3
Completed NCT01441336 - Laparoscopic Gastrectomy for Advanced Gastric Cancer Phase 2
Completed NCT01238055 - Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer Phase 2
Completed NCT02071043 - Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis Phase 2